Method for co-application of gases and drugs to potentiate their action in relieving headaches, angina and other ailments
AssigneeCapnia, Inc.
InventorsNed S. Rasor, Julia S. Rasor
Life of this patent
Estimating the term…
Abstract
Apparatus, methods and kits for treating symptoms associated with common ailments such as headaches, rhinitis, asthma, epilepsy, nervous disorders and the like, are provided. The apparatus includes dispensers for carbon dioxide and other therapeutic gases. The methods include delivering small volumes of these gases to patients in a manner where the gas infuses a body region in order to bathe the mucous membranes therein. It has been found that even very short exposure of patients to small volumes and high concentrations of such gases can provide significant relief from symptoms.
Claims24
A method for controlling the effect of a drug on an individual comprising:
- administering the drug;
- generating a flow of a gaseous physiologically active agent;
- and
- infusing at least one facial orifice of the individual with the gaseous, physiologically active agent to enhance the action of the drug, wherein the orifice is selected from the group consisting of a nostril and a mouth, and wherein the individual substantially inhibits the passage of the gaseous physiologically active agent into the trachea and lungs by limiting inhalation of the gaseous physiologically active agent.
A method for controlling the effect of a drug on an individual having a mucous membrane, trachea and lung comprising:
- administering the drug;
- creating an environment of a gaseous physiologically active agent;
- and
- exposing the mucous membrane to the environment of the gaseous physiologically active agent to enhance the action of the drug, while substantially preventing the entry of the gaseous physiologically active agent into the trachea and lung, and wherein the mucous membrane is selected from the group consisting of nasal mucous membrane and oral mucous membrane.
A method of controlling the effect of nitroglycerin for the treatment of an ailment selected from a group consisting of angina and myocardial infraction in an individual having a mucous membrane, trachea and lung, said method comprising:
- administering the nitroglycerin;
- creating an environment comprising carbon dioxide gas in a higher concentration than that found in exhaled breath;
- exposing the mucous membrane to the environment while substantially preventing the entry of the carbon dioxide gas into the trachea and lung, and wherein the mucous membrane is selected from the group consisting of nasal mucous membrane and oral mucous membrane.
A method of controlling the effect of a drug for the treatment of symptoms selected from a group consisting of headache and respiratory distress in an individual having a mucous membrane, trachea and lung comprising:
- administering the drug;
- creating a gaseous environment comprising CO2 in a higher concentration than that found in exhaled breath;
- exposing the mucous membrane to the environment to enhance the action of the drug while substantially preventing the entry of the gaseous environment into the trachea and lung and wherein the mucous membrane is selected from the group consisting of nasal mucous membrane and oral mucous membrane.
A method of controlling the effect of NO in an individual having a mucous membrane, trachea and lung comprising:
- generating a flow of NO;
- infusing at least one facial orifice of the individual with the flow of NO;
- creating an environment of essentially pure carbon dioxide gas having a purity of at least 50% by volume;
- exposing the mucous membrane of the individual to the environment, wherein the mucous membrane is selected from the group consisting of nasal mucous membrane and oral mucous membrane.
A method of controlling the effect of NO in an individual having a mucous membrane, trachea and lung comprising:
- generating a flow of NO;
- infusing at least one facial orifice of the individual with the flow of NO;
- creating an environment of CO2 in a higher concentration than that found in exhaled breath;
- exposing the mucous membrane to the environment of CO2 to enhance the action of the NO, while substantially preventing the entry of the CO2 into the trachea and lung, wherein the mucous membrane is selected from the group consisting of nasal mucous membrane and oral mucous membrane.
A method for controlling the effect of a drug on an individual having mucous membrane comprising:
- administering the drug;
- creating a gaseous environment of essentially pure CO2 having a purity of at least 50% by volume;
- exposing the mucous membrane to the environment to enhance the action of the drug, and wherein the mucous membrane is selected from the group consisting of nasal mucous membrane and oral mucous membrane, wherein the patient substantially refrains from inhalation of the CO2.
Dependencies are inferred from the claim text.